Natera Inc (NTRA) Stake Lessened by EAM Investors LLC
EAM Investors LLC trimmed its position in shares of Natera Inc (NASDAQ:NTRA) by 29.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 145,774 shares of the medical research company’s stock after selling 59,769 shares during the quarter. EAM Investors LLC owned 0.24% of Natera worth $3,490,000 at the end of the most recent quarter.
Several other institutional investors have also recently modified their holdings of NTRA. Jennison Associates LLC increased its stake in shares of Natera by 39.1% during the third quarter. Jennison Associates LLC now owns 3,641,848 shares of the medical research company’s stock worth $87,186,000 after acquiring an additional 1,024,225 shares during the period. Peregrine Capital Management LLC acquired a new position in shares of Natera during the third quarter worth about $12,831,000. Millennium Management LLC increased its stake in shares of Natera by 135.5% during the second quarter. Millennium Management LLC now owns 744,598 shares of the medical research company’s stock worth $14,013,000 after acquiring an additional 428,376 shares during the period. BlackRock Inc. increased its stake in shares of Natera by 19.4% during the second quarter. BlackRock Inc. now owns 2,086,829 shares of the medical research company’s stock worth $39,274,000 after acquiring an additional 338,766 shares during the period. Finally, Zions Bancorporation acquired a new position in shares of Natera during the third quarter worth about $6,319,000. Institutional investors and hedge funds own 80.39% of the company’s stock.
In other Natera news, insider Jonathan Sheena sold 166,667 shares of the stock in a transaction that occurred on Friday, September 14th. The shares were sold at an average price of $24.27, for a total transaction of $4,045,008.09. Following the transaction, the insider now owns 481,975 shares of the company’s stock, valued at $11,697,533.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Matthew Rabinowitz sold 403,462 shares of the stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $24.90, for a total transaction of $10,046,203.80. Following the completion of the sale, the chief executive officer now directly owns 1,701,686 shares of the company’s stock, valued at approximately $42,371,981.40. The disclosure for this sale can be found here. Insiders have sold 2,014,988 shares of company stock worth $48,674,710 in the last three months. Insiders own 13.18% of the company’s stock.
Shares of NASDAQ NTRA opened at $16.78 on Monday. Natera Inc has a 12-month low of $8.60 and a 12-month high of $29.62. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -6.99 and a beta of 2.11. The company has a current ratio of 2.44, a quick ratio of 2.32 and a debt-to-equity ratio of 1.30.
Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, November 8th. The medical research company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.03). Natera had a negative net margin of 58.00% and a negative return on equity of 2,569.52%. The business had revenue of $65.30 million during the quarter, compared to analysts’ expectations of $66.42 million. During the same period last year, the company earned ($0.51) EPS. The firm’s revenue for the quarter was up 16.8% on a year-over-year basis. On average, equities analysts predict that Natera Inc will post -2.11 EPS for the current fiscal year.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Further Reading: How are Outstanding Shares Different from Authorized Shares?
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera Inc (NASDAQ:NTRA).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.